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Vaccines  have  led to signiﬁcant  reductions  in  morbidity  and saved  countless  lives  from  many  infectious
diseases  and are  one  of the  most  important  public  health  successes  of the modern  era.  Both  vaccines’
effectiveness  and  safety  are keys  for the  success  of  immunisation  programmes.  The  role  of  post-licensure
surveillance  has  become  increasingly  recognised  by regulatory  authorities  in the  overall  vaccine  devel-
opment  process.  Safety,  purity,  and  effectiveness  of  vaccines  are  carefully  assessed  before  licensure,  but
some safety  and  effectiveness  aspects  need  continuing  monitoring  after  licensure;  Post-marketing  activ-
ities  are  a necessary  complement  to pre-licensure  activities  for monitoring  vaccine  quality  and  to  inform
public  health  programmes.  In  the  recent  past,  the  availability  of large  databases  together  with data-
mining  and  cross-linkage  techniques  have  signiﬁcantly  improved  the  potentialities  of post-licensure
surveillance.  The  scope  of  this  review  is  to  present  challenges  and  opportunities  offered  by  vaccine  post-
licensure  surveillance.  While  pre-licensure  activities  form  the foundation  for  the development  of  effective
and  safe  vaccines,  post-licensure  monitoring  and  assessment,  are  necessary  to  assure  that  vaccines  are
effective and  safe  when  translated  in  real  world  settings.  Strong  partnerships  and  collaboration  at  an  inter-
national  level  between  different  stakeholders  is necessary  for ﬁnding  and  optimally  allocating  resources
and  establishing  robust  post-licensure  processes.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Since the end of the XVIII century, when the ﬁrst human pro-
hylactic vaccine was developed, the number of vaccines available
or preventing infectious diseases slowly increased until the mid-
wentieth century. Antitoxins and bacterial vaccines were mainly
eveloped, but a major breakthrough, represented by the ability
o grow viruses in cell cultures, launched a new era for vaccino-
ogy [1]. Since then, the number of diseases that can be prevented
y vaccination increased exponentially. Today, 25 diseases are
accine preventable [2]. Poliomyelitis, diphtheria, tetanus, pertus-
is, hepatitis B, Haemophylus inﬂuenzae type B, measles, mumps,
ubella, pneumococcal infections, rotavirus, disease caused by
uman papillomavirus, and tuberculosis are targeted by childhood
accination programmes worldwide [3]. Moreover, new technolo-
ies in vaccine development dramatically increased the complexity
f modern vaccines: synthetic antigens, innovative adjuvants, and
onjugated proteins are components of many vaccine products
∗ Corresponding author. Tel.: +46 0 8 58 60 12 12; fax: +46 8 58 60 12 96.
E-mail address: pierluigi.lopalco@ecdc.europa.eu (P.L. Lopalco).
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
currently in use. Such increased complexity brings important
challenges during both the authorisation process and the post-
marketing phase in terms of assessment of both effectiveness and
safety.
Vaccine products reach marketing authorisation after a long
development phase that might last as long as 12–15 years [4]. Pre-
clinical studies (in vitro and in vivo) are necessary to select the
correct antigenic content so that clinical trials can be designed to
be as safe as possible. Phase 1 trials provide preliminary informa-
tion on vaccine safety in humans and on the dose to be tested in the
following clinical trials. They typically involve a limited number of
adult volunteers (<100). Candidate vaccines that show promise in
pre-clinical evaluation and Phase 1 trials undergo Phase 2 trials in
order to further evaluate the dose and safety and immunogenicity.
Phase 2 trials usually involve few hundreds of subjects belonging
to the ﬁnal target population of the vaccine (e.g., children for child-
hood vaccines). Phase 2 studies last until the right dose and vaccine
schedule is identiﬁed (usually a few years). The ﬁnal candidate
products progress to Phase 3, when they are studied on a larger
scale (from many hundreds to many thousands of subjects) to fur-
ther assess safety and immunogenicity or efﬁcacy against the target
disease. Generally, concomitant administration with other vaccine
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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roducts is also tested in Phase 3 trials, but it can be done even ear-
ier in the development phase [4]. Results from successful vaccine
rials are submitted to the regulatory authorities for further eval-
ation and determination of whether market authorisation should
e granted or not.
Demonstration of effectiveness may  be derived from clinical
ndpoint efﬁcacy studies. In some cases, immunogenicity data
ay  be sufﬁcient for a demonstration of effectiveness and clinical
ndpoint efﬁcacy data are not required. Whether immunogenic-
ty data provide sufﬁcient evidence of effectiveness depends on
he strength of evidence that the immune response endpoints pre-
ict clinical protection and whether there are sufﬁciently validated
ssays to measure those endpoints. In such cases, immunogenicity
s considered a good proxy for vaccine efﬁcacy. This is the case for
ertain new Hib, Td, or Hepatitis B vaccines since for these diseases
here are scientiﬁcally well-accepted immunological markers that
redict protection and that can be reliably measured in a validated
ssay.
After marketing authorisation has been granted, Phase 4 tri-
ls and other post-licensure surveillance activities can be carried
ut. Their scope is primarily to assess long-term effectiveness and
otential safety concerns that were not statistically signiﬁcant in
hase 3 trials but merit monitoring in the post licensure setting.
accine effectiveness assessed during the post-marketing phase is
he result of direct vaccine efﬁcacy combined with herd immunity.
hase 4 studies are very often an integral part of the authorisation
rocess in terms of post-marketing action required by the regu-
atory agencies to the vaccine manufacturers. Phase 4 studies are
omplemented by other post-licensure surveillance activities that
re carried out by different agents (public health institutions, uni-
ersities, research groups) as part of their public health mission.
The role of post-licensure surveillance has become increas-
ngly important during the last decades. New methodologies have
een developed to enhance efﬁciency and feasibility of post-
icensure surveillance [5,6]. These include various mechanisms to
utomate screening for signals in spontaneous reporting systems,
uch as empirical Bayesian data mining to identify unexpectedly
requent vaccine-event combinations [7]. More recently, avail-
bility of large healthcare databases opened a new season for
ost-licensure surveillance by using cross-linkage and data-mining
echnologies to rapidly monitor the safety of new vaccines [8]. With
enominator data on doses administered and the ready availabil-
ty of appropriate comparison (i.e., unvaccinated) groups, these
arge databases provide an economical and rapid means of con-
ucting post-licensure studies of safety and effectiveness. Both
ctive and passive surveillance systems have been implemented in
any countries and application of similar standards across national
oundaries has been advanced by the International Conference on
armonization [9] and the Brighton Collaboration [10].
The scope of this review is to present challenges and opportuni-
ies offered by vaccine post-licensure surveillance; and to discuss
ow, under the current authorisation framework in the US and EU,
ost-licensure surveillance can best complement Phase 3 trials.
. The European and U.S. authorisation and public health
rameworks for vaccine products
In the U.S., regulation of vaccines and other biological products
egan with the enactment of the Biologics Control Act of 1902 fol-
owing an immunisation safety incident in which several children
ied after receiving diphtheria antitoxin that had been contami-
ated with tetanus toxin [10]. The authority to control biologics
volved and was strengthened with the passage of additional laws
nd regulations in subsequent years. One of the major laws was
nacted as a result of another vaccine safety tragedy—the “Cutterine 33 (2015) 1541–1548
incident” in 1955, in which some batches of polio vaccine had been
inadequately inactivated, resulting in polio in several vaccine recip-
ients and their contacts [11]. As a result, the U.S. Congress directed
the creation of a new division at the National Institute of Health
(NIH) for the regulation of biological products (Division of Biolog-
ical Standards). Currently, regulatory authority for licensure (i.e.,
market authorisation) of vaccines rests with the Food and Drug
Administration (FDA) Center for Biologics Evaluation and Research.
The process of regulation and testing of vaccines has been previ-
ously reviewed by Baylor and Midthun [10]. There are a number of
processes in the FDA pre-licensure review process. For instance, for
a Biological License Application—an interdisciplinary committee of
many FDA regulatory scientists review the application including
clinicians, statisticians and other experts who review the clini-
cal studies and other data submitted. Other experts may  inspect
manufacturer facilities, conduct potency/purity testing, and other
evaluations. Also, during pre-licensure the FDA reviews sponsor
pharmacovigilance plans, may  request post-market commitments,
and in some cases may  mandate post-market requirements. Rec-
ommendations for routine use of vaccines are issued by the Centers
for Disease Control and Prevention (CDC), with guidance from its
Advisory Committee on Immunization Practices [12].
In the U.S., programs to systematically monitor vaccine safety
in the post-licensure setting began in the late 1970s. Established
by CDC in 1978, the Monitoring System for Adverse Events Follow-
ing Immunizations (MSAEFI) collected reports of adverse events in
children who  received publicly funded vaccines [13]. The National
Childhood Vaccine Injury Act (NCVIA) of 1986 was  landmark
legislation that established the Vaccine Injury Compensation Pro-
gram and the Vaccine Adverse Event Reporting System (VAERS),
which replaced MSAEFI in 1990. Subsequently, as is described
below, other systems have been put in place by CDC and FDA for
population-based active surveillance based on cross-linking large
healthcare or insurance databases.
In Europe, the European Medicines Agency (EMA) was  estab-
lished in 1995 as a decentralised agency of the European Union
(EU) for the evaluation of medicines for use in member countries.
Thanks to a centralised procedure, pharmaceutical companies may
submit one single marketing-authorisation (MA) application to the
EMA. Scientiﬁc evaluation of the MA  is carried out by scientiﬁc
committees coordinated by the EMA. The Committee for Medicinal
Products for Human Use (CHMP), the Paediatric Committee (PDCO)
and the Pharmacovigilance Risk Assessment Committee (PRAC) are
those more involved with vaccine products. Committees’ members
are nominated by the medicines regulatory authorities of the EU
Member States, so that geographical representativeness is granted
and national interests represented. Representatives of patients and
healthcare-professionals may  also be part of the committees. Ad
hoc working parties are also established in order to provide recom-
mendations to the scientiﬁc committees for certain speciﬁc issues.
In particular, a Vaccine Working Party has been operational since
2005.
The scientiﬁc committee that is in charge of evaluating a MA
application appoints a rapporteur to lead the assessment. The rap-
porteur is supported by an assessment team and can ask for a
peer-reviewed process in order to improve the scientiﬁc validity of
the process. National authorities that provide the staff for the pro-
cess are remunerated by the EMA. Opinions and recommendations
presented by the rapporteur are usually adopted in plenary sessions
of the scientiﬁc committees. If consensus cannot be achieved, the
ﬁnal position is reached through a vote. On the basis of EMA  scien-
tiﬁc assessment, the European Commission may  grant a MA  issuing
a legally binding EU-wide decision. Vaccines that are authorised
through this centralised process can be marketed in any country
of the EU and European Economic Area (EEA-including Iceland,
Norway and Liechtenstein).
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Table 1
Factors affecting vaccine effectiveness.
Host factors
Age
Presence of conditions/co-morbidities that may either affect immune
response or inﬂuence individual disease susceptibility
Previous exposure to antigen
Interference due to co-administered vaccines or other drugs
Logistic issues
Schedule compliance
Cold chain
Administration issues
Epidemiological factors
Force of infection
Herd immunityP.L. Lopalco, F. DeStefano 
Speciﬁc post-authorisation measures (PAM) may  be identiﬁed
y EMA’s committees during the scientiﬁc assessment phase and
re strictly regulated within a legislative framework [11]. PAM
re not intended to promote premature authorisation of medicinal
roducts, but are necessary when the manufacturer needs to pro-
uce additional data on safety and/or efﬁcacy to complement data
roduced in the pre-authorisation phase [12]. Post-authorisation
afety studies (PASS), either active studies or meta-analyses, may
e carried out as part of PAM. In addition, post-authorisation
fﬁcacy/effectiveness studies may  be required as part of the risk
anagement plan submitted by the manufacturer as part of the
pplication ﬁle.
. Methodological aspects of Phase 3 trials: Strengths and
imitations
Phase 3 trials are considered the gold standard to assess
accine efﬁcacy in the pre-authorisation phase. Well-designed dou-
le/triple blinded, randomised, controlled trials (RCT) provide a
ery robust estimate of vaccine efﬁcacy under standard conditions.
evertheless, some strengths of RCTs can turn into limitations from
 public health perspective. First of all, in RCTs vaccines are pro-
ided under very strict experimental conditions in terms of cold
hain, schedule, administration technique, etc; standard conditions
re necessary for experimental purposes and are also needed in the
arketing authorisation framework, but they may  not be strictly
dhered to in practice during daily vaccination activities. Moreover,
n RCTs controlled conditions are pursued as much as possible and
fﬁcacy estimates in vaccinated individuals may  not be inﬂuenced
y herd immunity; whereas, the real life impact of vaccination is
ffected by herd immunity, which is indeed highly desired under
 public health perspective. Post-licensure effectiveness evaluation
s useful both for vaccines that have been evaluated in pre-licensure
linical VE trials as well as those for which pre-licensure effec-
iveness was based on immunogenicity data. In addition, very rare
dverse events usually cannot be identiﬁed during RCTs, due to nat-
ral limitations in terms of sample size and study power [13,14].
eﬁnitely, RCTs represent the best way to assess vaccine efﬁcacy,
ut the information they can provide needs to be supplemented to
upport public health decision making post-licensure.
Evaluation of safety in Phase 3 trials provides the most reli-
ble information on reactogenicity (e.g., injection site reactions,
ever) and relatively common adverse events. Phase 3 trials, how-
ver, are usually not large enough to adequately evaluate risks for
are adverse events. Also, Phase 3 trials may  not last long enough
o detect adverse events with a delayed onset and particular sub-
roups may  not be included in the trials (e.g., pregnant women).
. Methodologies for post-licensure surveillance
.1. Effectiveness assessment
Vaccine effectiveness can be deﬁned as the ability of a vaccine
o prevent speciﬁc outcomes in a “real life” situation. Assessing
accine effectiveness is necessary in order to establish the actual
eneﬁt of the vaccination in the ﬁeld. Vaccine effectiveness esti-
ates may  signiﬁcantly differ from vaccine efﬁcacy measured
uring vaccine trials. In fact they may  be inﬂuenced by several
actors that are summarised in Table 1.
Several methodologies have been developed for assessing vac-
ine effectiveness in the ﬁeld, each of them presenting strengths
nd limitations [5,6,15–22]. Strengths and limitations of some of
hose methodologies that have been extensively used in the recent
ast are summarised in Table 2.Mismatch with circulating strains
Emergence of new viral/bacterial variants
Vaccine effectiveness measured in the ﬁeld may  provide evi-
dence for decision making that may  not be available at the time of
marketing authorisation. Herd immunity effects, degree of match-
ing with circulating strains, impact of waning immunity, and
changes in microbial ecology induced by vaccination are some
of the conditions that can be analysed only by means of post-
licensure surveillance. The ability to address such issues represents
an evident added value of post-licensure surveillance and makes
post-licensure surveillance a valuable complement to Phase 3 stud-
ies.
4.2. Safety assessment
Passive surveillance of adverse events following immunisation
(AEFI) and adverse events of special interest (AESI) is mandatory
after vaccine marketing both in the US and EU. Passive sponta-
neous reporting systems can be valuable for identifying potential
new safety concerns (i.e., “signals”), but they are subject to sev-
eral limitations that limit their utility for causality assessment
(Table 3). The main limitations include underreporting and other
reporting biases, such as stimulated reporting when a new vaccine
is introduced or following media attention on a possible vaccine
safety issue. There may  also be inconsistent data quality and com-
pleteness in the reports. Moreover, reports are only submitted on
individuals who were vaccinated and developed an adverse event;
data are usually lacking on the number of people vaccinated and on
the occurrence of the adverse event in people who  were not vacci-
nated. Thus, it is not possible to assess if risk is higher in vaccinated
individuals relative to an unvaccinated comparison group.
The Vaccine Adverse Event Reporting System, co-managed
by CDC and FDA, is the US spontaneous reporting system for
adverse events after vaccination [23]. VAERS accepts reports from
healthcare providers, manufacturers, vaccine recipients, and oth-
ers. Healthcare providers are required to report AEs listed in the
VAERS Table of Reportable Events following Vaccination and are
encouraged to report other clinically signiﬁcant AEs after vac-
cination. Reported AEs are entered into a database and coded
using Medical Dictionary for Regulatory Activities (MedDRA) terms.
Physicians and scientists at FDA and CDC regularly review the
VAERS reports and conduct periodic safety assessments. FDA has
regulatory requirements to conduct scheduled safety assessments
of speciﬁc vaccines. De-identiﬁed VAERS data also are available for
viewing and analysis by the public.
All drugs that are centrally authorised in the EU – vaccines
included – are subject to mandatory passive surveillance of adverse
events at the European level. Individual reports of adverse events
are managed through the EudraVigilance system [24]. Both reports
from studies carried out by the manufacturers and spontaneous
1544 P.L. Lopalco, F. DeStefano / Vaccine 33 (2015) 1541–1548
Table 2
Some strengths and limitations of different methodologies for assessing vaccine effectiveness.
Method Strengths Limitations
Screening method • Use of routinely collected data
• Rapid and not expensive
• Suboptimal accuracy and completeness of
routinely collected data
• Does not provide precise estimates of vaccine
effectiveness
Outbreak investigation • Good estimates provided under certain
circumstances (closed communities, low disease
incidence in the past, high attack rates)
•  During community-wide outbreaks cluster sampling
can be performed
• Control programmes during the outbreak can
severely interfere
• Exposure can be different among vaccinees and
non-vaccinees
Coverage survey method • Similar approach as in outbreak investigation, but
does not require any actual outbreak
• Similar resources required as for coverage survey
• Exposure can be different among vaccinees and
non-vaccinees
•  Can be used only in endemic areas
•  Recall bias may  affect the accuracy of case
ascertainment
Secondary attack rates in households or
clusters
• Bias due to different exposure among vaccinees and
non-vaccinees is reduced
• Small number of children available
• Families should be followed-up for a time longer
than the incubation period
• Method of secondary attack rates in clusters is
less rigorous
Case-control studies • Good use of resources
•  Useful when access to data from clinics is easier than
access to vaccination records
• Correct selection of controls is crucial to limit bias
• Potential confounders must be seriously
addressed
Time-series analysis • Use of routinely collected data
• May  evaluate both direct and indirect (herd
immunity) vaccination effects
• Limits of any ecological approach
Indirect cohort design • More efﬁcient than cohort studies
 (pneu
• May  under-estimate vaccine effectiveness
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eports by healthcare professionals and regulatory agencies are
aptured by the system. Data from EudraVigilance are published in
he European database of suspected adverse drug reaction reports
25]. Individual suspected-side-effect reports sorted by age group,
ex, type of suspected side effect and outcome, can be viewed by any
xternal user. No pharmacovigilance system speciﬁc for a vaccine
roduct is in place in the EU.
Assessment of passive AEFI reports is carried out by the EMA
egularly, according to the risk management plan. Routine analysis
f EudraVigilance reports – for detecting any potential signal – is
erformed at least monthly; for some medicines, including some
accines, it is done bi-weekly.
While AEFI passive surveillance is quite effective for signal
etection purposes, formal epidemiologic studies are needed for
ausality assessment. In addition to traditional methodologies,
uch as cohort and case-control studies, case-only methods have
een developed in order to improve feasibility of AEFI causality
ssessment in pharmacovigilance settings [26]. Case-only studies
rovide the great advantage of using cases as their own  control
roup, avoiding the need to select external controls. Case-only
ethods are particularly advantageous for assessment of rare
EFI and in situations of possible indication bias (e.g., certain
accines that may  be indicated for particular high risk groups).
dentifying appropriate risk and comparison intervals, however,
an be challenging. Moreover, case-only methods are best suited
or conditions with acute onset; they may  difﬁcult to apply to
onditions with an insidious onset.
able 3
ome strengths and limitations of spontaneous reporting systems.
Strengths Limitation
• Rapid signal detection (hypothesis generation) • Reportin
•  Cover large population • Inconsist
•  Can detect rare adverse events • Lack of u
•  Relatively inexpensive • Not desigmococcal infections) because cross protection against non-vaccine types
cannot be controlled
Analytical studies for AEFI causality assessment are facilitated
by the availability of large databases collecting information on
any event of medical interest in large cohorts of vaccinees. Large
databases and cross-linkage techniques have allowed the recent
development of new kinds of analyses that would have been impos-
sible a few decades ago. The US Vaccine Safety Datalink (VSD)
is the oldest such database infrastructure for monitoring vac-
cine safety. Recognising the need for a ﬂexible, timely and robust
system to evaluate vaccine safety and supplement information
provided by VAERS, CDC established VSD in 1990 to conduct post-
marketing vaccine safety evaluations in deﬁned populations [27].
As a collaboration between CDC and several large health care orga-
nisations, VSD conducts population-based monitoring and research
on important immunisation safety questions. VSD has the capacity
to address a wide array of safety issues, including monitoring new
vaccines in children and adults and conducting timely evaluations
of new vaccine safety signals. The aggregate population across all
sites is sufﬁciently large so that risk can be assessed for rare adverse
events. Data from approximately 9.3 million individuals are avail-
able annually, including 2.1 million children and 7.2 million adults.
VSD has cumulative information on more than 21 million indi-
viduals who have collectively received over 134 million vaccine
doses. Building on the VSD model, FDA has recently established
the Post-Licensure Rapid Immunization Safety Monitoring (PRISM)
system that links data from several large health insurance compa-
nies. PRISM is integrated within the Mini-Sentinel project [28] and
enhances the national capacity for vaccine safety monitoring by
s
g bias (e.g., underreporting, stimulated reporting) routinely collected data
ent data quality and completeness
nvaccinated comparison group
ned to assess if a vaccine caused an adverse event
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ssembling vaccination and outcomes data on an additional large
opulation covering tens of millions of people, providing further
apabilities to evaluate rare adverse events [29].
In Europe, the VAESCO (Vaccine Adverse Event Surveillance &
ommunication) consortium has been initiated and sponsored by
he ECDC with the aim of improving the sensitivity and timeliness
f vaccine safety monitoring systems [30]. A network of national
ublic health institutes and national pharmacovigilance authori-
ies from 10 EU countries, coordinated by Erasmus University (The
etherlands) and Brighton Collaboration (Switzerland) have been
ollaborating on speciﬁc projects related to vaccine safety. VAESCO
artners have developed standards and methods for vaccine safety
ssessment and have conducted epidemiologic studies based on
inking large health care databases. Large database linkage has been
uccessfully used by VAESCO on several occasions, setting the basis
or a European Vaccine Safety Datalink system [31–33].
Perhaps as important as the technological advances in estab-
ishing and cross-linking large healthcare databases, has been the
evelopment of analytical methods to fully capitalise on the oppor-
unities offered by such databases for timely and valid assessments.
arious methods, such as maximised sequential probability ratio
ests [34] and group sequential monitoring [35], have been devel-
ped for near real-time sequential analysis of surveillance data.
daptation of risk-interval designs, including self-control [26] and
ase-centred methods [36], has been instrumental in addressing
nalytical challenges posed by analyses of highly vaccinated popu-
ations and potential confounding by indication.
. Illustrative case studies of the added value of
ost-licensure surveillance
.1. Effectiveness of acellular pertussis vaccines
Acellular pertussis vaccine trials have represented one of the
iggest public investments in the history of vaccine development.
y the mid-1980s the US NIH, worried about the increasing pub-
ic concern about the safety of cellular pertussis vaccines, boosted
esearch on acellular vaccines [37]. Large acellular pertussis tri-
ls were conducted in the 1990s, assessing safety and efﬁcacy
f DTaP vaccines in infants [38,39]. Efﬁcacy estimates from the
hase 3 trials were very consistent, showing protective efﬁcacy
f more than 80% in children vaccinated with acellular vaccines;
n the other hand efﬁcacy of cellular vaccines was  very variable.
oreover, acellular vaccines showed much higher tolerability [40].
s a consequence, beginning in the late 1990’s acellular vaccines
apidly replaced cellular vaccines both in the US and in Europe and
accine coverage against pertussis increased [41]. Notwithstand-
ng high coverage rates, resurgence of pertussis has been recently
eported both in the US and in Europe; in particular, high inci-
ence rates have been reported in adolescents and young adults
s well as small infants [42–45]. The increase has been attributed
o different factors, including earlier than expected waning of
mmunity; a shift of pertussis circulation in those age groups not
overed by vaccination and subsequent transmission to unvacci-
ated infants; and possible vaccine failure due to emergence of
ordetella pertussis mutant strains [44,46–50]. Whatever the rea-
on, the resurgence of pertussis indicates a need for a revision
f current pertussis vaccination strategies guided by a thorough
ssessment of pertussis epidemiology and vaccine effectiveness.
he unexpected resurgence of pertussis in some countries, how-
ver, is not in contradiction with the reported high vaccine efﬁcacy
fter Phase 3 trials. Even in the presence of high individual efﬁcacy
fter primary vaccination [38,39] and reasonably good sustained
fﬁcacy after 5 years [51,52], infant vaccination alone seems to
e far from sufﬁcient to stop the overall circulation of B. pertus-
is. Alternative strategies including adolescent/adult vaccinationne 33 (2015) 1541–1548 1545
[45,53–55] and vaccination in pregnancy [56] have been imple-
mented in many countries. In order to inform new vaccination
strategies and to better understand the reasons behind pertussis
resurgence, both disease and vaccine post-licensure surveillance
are paramount [57–60].
5.2. Effectiveness of Inﬂuenza vaccines
Immunogenicity and safety of inﬂuenza vaccines is system-
atically assessed by means of Phase 3 trials for MA  purposes.
Unfortunately, due to the frequent drifts and shifts of inﬂuenza
viruses, pre-licensure trials, carried out for regulatory purposes,
do not always anticipate the impact of inﬂuenza vaccination pub-
lic health campaigns. Several systematic reviews of the literature
reported limited impact of inﬂuenza vaccination in children below
2 years, healthy adults, and the elderly [61–63]. Mismatch between
vaccine and circulating strains is one of the most important fac-
tors for low inﬂuenza vaccine effectiveness. Thus, inﬂuenza vaccine
effectiveness should be routinely measured in order to better
understand the role and impact of vaccination strategies under dif-
ferent epidemiological circumstances. For this purpose, the US  Flu
VE Network [64] was  established and the I-MOVE network was
established in Europe in 2007. Repeated estimates of inﬂuenza
vaccine effectiveness have been provided by I-MOVE throughout
different inﬂuenza seasons [21]. Not surprisingly, one of the high-
est vaccine effectiveness estimates (71.9%; 95% conﬁdence interval
45.6–85.5) has been reported during the 2009–10 season, when the
pandemic A(H1N1)pdm09 virus was the almost exclusive circulat-
ing strain and was  well matched to the vaccine strain [22]. Although
the Flu VE Network has recently begun to provide interim within
season estimates of inﬂuenza vaccine [65], effectiveness estimates,
have usually been available a few months after the inﬂuenza season
is over and may not be applicable to the next season (i.e., because
of strain changes). Nevertheless, continuing evaluation of inﬂuenza
vaccine effectiveness can provide important information for public
health decisions in terms of vaccine effectiveness in different age
groups, the added value of adjuvants, and the effectiveness of differ-
ent vaccine types. Increasing knowledge on the impact of inﬂuenza
vaccination is of high value for public health.
5.3. European experience: Pandemrix and narcolepsy
In August 2010 public health authorities in Finland and Sweden
reported an increase of cases of narcolepsy in children and
adolescents, suggesting a potential association with Pandem-
rix vaccination. Eight inﬂuenza A(H1N1)pdm09 vaccines were
licensed for use in Europe during the 2009 pandemic, but Pandem-
rix was  the most frequently used vaccine in Europe: based on EMA
estimates, more than 30.5 million people were vaccinated with
Pandemrix in the EU/EEA [66]. In Finland and Sweden, Pandemrix
was the only vaccine used for the pandemic vaccination campaign.
Narcolepsy is a rare neurological disorder characterised by
inability to regulate sleep-wake cycles normally. The primary
symptom is excessive daytime sleepiness. Narcolepsy predom-
inantly affects adolescents and young adults, and very rarely
children under 16 years of age. Sudden onset of short episodes of
muscle tone loss, known as cataplexy, may  occur as part of the
neurological disorder [67]. Abnormal immunological response to
different antigens, combined with speciﬁc genetic patterns, is sus-
pected to be the trigger for narcolepsy [68,69].
The VAESCO consortium, supported by the ECDC, coordinated
a multinational investigation to assess the causality relationship
between narcolepsy and Pandemrix [30]. Eight European countries
(Denmark, Finland, Italy, the Netherlands, Norway, Sweden, and the
United Kingdom) participated in a case-control study using a com-
mon protocol, common case report forms, and a common Brighton
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ollaboration case deﬁnition. This study conﬁrmed a strong sta-
istical association between Pandemrix and onset of narcolepsy in
hildren and adolescents in Finland and Sweden [66], in line with
ndependent analyses carried out by national authorities [70–73].
urther studies, carried out at national levels in Norway, Ireland,
nd England identiﬁed an association in those countries as well
74–76].
In conclusion, after the signal raised in Finland and
weden, a strong association between narcolepsy and inﬂuenza
(H1N1)pdm09 vaccination has been established in some Euro-
ean countries, but not in others and nowhere else outside Europe.
t is still unknown if the vaccine was the cause of the neurological
isorder or if it was just the trigger speeding up disease onset
n individuals who would otherwise have developed narcolepsy
ater. This will become clear in the coming years, as results become
vailable from studies in other countries as well as research on the
athogenic mechanisms of narcolepsy that has been stimulated
y this event. In this episode, post-licensure surveillance was
emonstrated to be effective in detecting a signal of a serious
EFI at national levels, and international collaboration has been
xtremely fruitful for the following signal assessment.
.4. Rotashield and intussusception
The ﬁrst vaccine designed to prevent rotavirus infection
Rotashield®–Wyeth Lederle Vaccines, Philadelphia, PA) was  vol-
ntarily withdrawn from the US market by the manufacturer in
999 due to an increased risk of intussusception among infants
eceiving the vaccine [77]. The identiﬁcation and investigation
f this safety problem provides an excellent illustration of a
ost-licensure vaccine safety monitoring system that worked
ell to inform vaccination policy. In the pre-licensure trials for
otashield®, a small increase in the number of cases of intussus-
eption had been observed, but the results were not statistically
igniﬁcant. As a result, FDA and CDC were on the alert to closely
onitor for intussusception after Rotashield® was licensed in
he US in August 1998 and subsequently recommended for uni-
ersal infant immunisation in March 1999. By May 1999, nine
ases of intussusception had been reported to VAERS following
otashield®, whereas VAERS had received only 3 reports of intus-
usception following all vaccines administered from 1990 to 1998.
n response to the VAERS signal, along with other data, CDC initiated
wo conﬁrmatory studies and suspended the recommendation for
otashield® vaccination pending the results of those studies. The
rst study was initiated in VSD and expanded to include 10 large
edical care organisations. Using the computerised databases of
he participating medical care organisations, with chart conﬁrma-
ion of intussusception cases, a cohort study was conducted that
ound a large increased risk of intussusception associated with
otashield® vaccination; the highest relative risk of 31 occurred
uring days 3–7 after the ﬁrst dose [78]. The second study was  a
arge case-control study conducted in 19 states, which also found
 strong association with Rotashield® with a peak relative risk of
6 at 3–7 days after the ﬁrst dose [79]. As a result of these ﬁndings,
n October 1999 the manufacturer stopped marketing the vaccine
nd ACIP withdrew its recommendation for the vaccine.
Two new rotavirus vaccines were subsequently licensed follow-
ng large pre-licensure trials that did not ﬁnd an increased risk
f intussusception. In post-licensure monitoring, however, a small
ncreased risk of intussusception was detected for both vaccines
80,81]. Post licensure data have also documented large beneﬁts
f rotavirus vaccination in terms of reductions in hospitalisations,
R visits, and in some cases, deaths from diarrhoea [82]. Thus, pol-
cy makers have continued to recommend the current rotavirus
accines for childhood immunisation programs.ine 33 (2015) 1541–1548
6. Conclusion
Pre-licensure activities form the foundation for the develop-
ment and licensure of effective and safe vaccines. Pre-licensure
activities, including the pivotal Phase 3 trials, cannot be replaced
by post-licensure monitoring systems. Post-licensure monitoring
and assessment, however, are necessary adjuncts to pre-licensure
activities to assure that vaccines are effective when translated
from the somewhat idealised clinical trial setting to wider popula-
tion groups in real world settings. After licensure, robust vaccine
safety monitoring systems are essential for providing assurance
of the safety of vaccines and rapidly identifying and responding
to potential safety problems, particularly rare health conditions
that pre-licensure trials may  not have had the power to detect.
Currently, spontaneous reporting systems serve as the principal
mechanisms for the early identiﬁcation of potential vaccine safety
problems. Spontaneous reporting systems, however, have many
limitations, with under-reporting being foremost among them.
Possible technological advances could be employed to improve
reporting completeness and accuracy, including application of
Web-based and text messaging technologies to make reporting
easier and more accurate.
An optimal vaccine safety monitoring system must include a
capability to rapidly conduct formal epidemiologic evaluations of
potential safety problems identiﬁed from spontaneous reporting
systems or other sources. This function can be most readily served
by the establishment of standing infrastructures of large linked
healthcare databases, such as the VSD project. The diffusion of elec-
tronic health records and the capability to link records across health
data systems and immunisation registries may  allow the expansion
of populations that could be included in post-licensure epidemio-
logic evaluations of vaccine safety.
New technologies and innovative epidemiological methods also
can be beneﬁcial to improve post-licensure assessment of vaccine
effectiveness and impact on population health. Data on disease epi-
demiology, disease burden, vaccine coverage, vaccination status of
disease cases are necessary for effectiveness and impact assess-
ment. Those data are usually available in different databases hosted
by different public health agencies. Strong partnerships between
regulatory and public health authorities as well as academia and
vaccine manufacturers would be necessary to facilitate such activ-
ities. Moreover, due to the large sample size required for those
kinds of studies, international collaboration and coordination is
paramount. The legal regulatory framework also plays a cru-
cial role: enhancing the importance of post-licensure surveillance
in the regulatory process could facilitate allocation of adequate
resources and foster collaboration among all involved stakeholders.
Vaccines are one of the most important public health successes
of the modern era. They have led to signiﬁcant reductions in mor-
bidity and saved countless lives from many infectious diseases. The
success of vaccination programs depends on both vaccines’ effec-
tiveness and their safety. Robust systems to monitor and evaluate
vaccines after they are licensed and are widely administered are
critical to maintaining the public’s conﬁdence in and acceptance of
vaccines, as well as to assure that the vaccines are providing the
level of protection and safety anticipated when they were licensed.
The ﬁndings and conclusions in this report are those of the
authors and do not necessarily represent the ofﬁcial policy or posi-
tion of the Centers for Disease Control and Prevention.
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